Alpha emitter radium-223 and survival in metastatic prostate cancer

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F13%3AE0103552" target="_blank" >RIV/00843989:_____/13:E0103552 - isvavai.cz</a>
Alternative codes found
RIV/00023001:_____/13:00059318
Result on the web
<a href="http://dx.doi.org/10.1056/NEJMoa1213755" target="_blank" >http://dx.doi.org/10.1056/NEJMoa1213755</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1056/NEJMoa1213755" target="_blank" >10.1056/NEJMoa1213755</a>

Result language
angličtina
Original language name
Alpha emitter radium-223 and survival in metastatic prostate cancer
Original language description
Background: Radium-223 dichloride (radium-223), an alpha emitter, selectively targets bone metastases with alpha particles. We assessed the efficacy and safety of radium-223 as compared with placebo, in addition to the best standard of care, in men withcastration-resistant prostate cancer and bone metastases. Methods: In our phase 3, randomized, double-blind, placebo-controlled study, we randomly assigned 921 patients who had received, were not eligible to receive, or declined docetaxel, in a 2:1 ratio, to receive six injections of radium-223 (at a dose of 50 kBq per kilogram of body weight intravenously) or matching placebo; one injection was administered every 4 weeks. In addition, all patients received the best standard of care. The primary end point was overall survival. The main secondary efficacy end points included time to the first symptomatic skeletal event and various biochemical end points. A prespecified interim analysis, conducted when 314 deaths had occurred, assessed th
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Publication year
2013
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)